Axogen, Inc. announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05). Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group (p-value <0.05).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.87 USD | +0.69% | -10.52% | -14.06% |
02/05 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
02/05 | Earnings Flash (AXGN) AXOGEN Posts Q1 Revenue $41.4M, vs. Street Est of $42.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.06% | 257M | |
+8.07% | 219B | |
+7.87% | 185B | |
+12.75% | 135B | |
-1.37% | 62.21B | |
+4.88% | 51.01B | |
+11.59% | 51.28B | |
+2.71% | 41.85B | |
+4.90% | 37.02B | |
+23.75% | 31.27B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study